DOCSLIB.ORG

Anti-Thrombotic Therapy: Management in the Upper Gastrointestinal Bleeding Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Thrombotic Therapy: Management in the Upper Gastrointestinal Bleeding Patient New anti-Thrombotic Therapy and Management in the Upper Gastrointestinal Bleeding Patient November 9th 2018 Col.Krit Opuchar, MD Department of Medicine, Phramongkutklao hospital Major disease Attributable to Disability-Adjusted Life Years Lost of Thai People by Sex US Population: Age 65+ & Cardiac disease Heidenreich et al. Circulation 2011 Changing Face of Antithrombotics Warfarin Prasugrel Rivaroxaban Apixaban 1954 2009 2011 2012 ASA Clopidogrel Dabigatran Ticagrelor Vorapaxar 1899 1998 2010 2011 2014 Major Causes of Death in Thailand, 1967-2009 Mortality per 100.000 population Year Thailand Healh Profile 2008-2010 Learning Objectives 1. Review the basics of bleed risk • Anticoagulants (warfarin, novel oral anticoagulant [NOAC]) • Antiplatelets (aspirin, thienopyridines and PAR-1 inhibitors) • Combination therapy (complex antithrombotic therapy [CAT]) 2. Highlight what is new 3. Discuss tricky situations • Stopping and restarting drugs in non-variceal upper gastrointestinal bleeding • Bridge therapy- what is the evidence? Antiplatelet: Site of Action Antiplatelets Decrease platelet aggregation and inhibit thrombus formation Vorapaxar : FDA Approves new PAR-1 inhibitor • Vorapaxar (Zontivity)–protease-activated receptor 1 (PAR-1) inhibitor • First-in-class antiplatelet medication • Approved January 2014 and now widely prescribed (concomitant with DAPT) • TRA 20 TIMI-50 trial (N=26,499) • 13% reduction of MI, stroke, CV death and need for revascularization procedures in patients with a previous MI or peripheral artery disease (v. placebo) • Increased risk of moderate or severe bleeding in 4.2% vs. 2.5% in placebo; 66% increased risk of bleeding overall • Black Box Warning: high risk of bleeding and contraindicated in patients with history of stroke, TIA and intracranial hemorrhage Gastric acid plays a central role in NSAID-associated gastroduodenal damage Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial: Life-threatening or major bleeding % of patients By aspirin dose, n=6293 4 3.5 3 2.5 2 1.5 1 0.5 0 <100 mg 100-150 mg 151-300 mg >300 mg Eur Heart J 2004;4:Suppl, 510 CURE: Aspirin Plus Clopidogrel All Bleeding Episodes % of patients 6 Aspirin Aspirin+Clopidogrel 5 4 P<0.01 3 2 1 0 <100 mg 110-162 mg >200 mg Eur Heart J 2004;4:Suppl, 510 Second Generation Thienopyridine Drugs: Rates of Bleeding Events • 2nd generation thienopyridine agents • Higher levels of platelet inhibition than clopidogrel >>>higher bleeding risk • Most common bleeding location>>>>>GI • Absolute increase greatest in elderly patients Bliden KP et al. Am Heart J 2011; Husted S et al. Circ Cardiovasc Qual Outcomes 2012; Cayla G QJM 2012; O’Gara et al. Circulation 2013. Evolution of Antiplatelet Therapy 25 20 25% 15 20% 19/16% CVD, MI or stroke Event(%) 10 Major bleeding 5 60% 38% 32/19% 1.3 2.4 0 0.8 1.8 None ASA ASA + Clopidogrel ASA + Clopidogrel or BMJ. 1994;308:81-106. Ticagrelor BMJ. 2002;324:71-86. N Engl J med. 2007;357:2001-15. N Engl J med. 2009;361:1045-57. Complex Antithrombotic Therapy (CAT) in Elderly Patients: GI Bleeding Outcomes One-Year Number Needed to Harm (NNH); N=78,133 Abraham NS et al. Circulation 2013. Steps for Minimizing Gastrointestinal Bleeding PPI Writing Committee Members et al. Circulation. 2008;118:1894-1909 Circulation. 2008;118(18):1894-1909. Copyright © American Heart Association, Inc. All rights reserved. Indications: Dual Antiplatelet Therapy •CurrentCirculation AHA 2013.and ACC Circulation guidelines 2013. include clopidogrel, ticagrelor and prasugrel Post-ACS Post-Stent • ASA indefinitely and clopidogrel or • Up to 12 months following unstable ticagrelor for: angina or NSTEMI managed without • Up to 12 months after Bare metal PCI stent (BMS) Placement • At least 14 days (12 months in some) • At least 12 months after drug- following STEMI eluting stent (DES) placement Circulation 2013. Risk of Clinical Events After Clopidogrel Cessation Among Patients with ACS Ho et al. JAMA 2008. Peptic Ulcer Bleeding: HRS Forrest Classification System Ia: Spurting Bleed Ib: Oozing Bleed IIb: Adherent IIa: NBVV Clot CARDIOGASTROENTEROLOGY TIP Stent Thrombosis Post-DES: Risk with Antiplatelet Cessation Short-term discontinuation of thienopyridine is safe in patients with DES if ASA therapy maintained Eisenberg M et al. Circulation 2009. CARDIOGASTROENTEROLOGY TIP ASA After Endoscopic Control of Peptic Ulcer Bleeding • Low-dose ASA (n=78) vs. placebo (n=78) • 30-day recurrent bleeding: 10.3% vs. 5.4% RCT • ARR: 4.9%; NNT=20 • 30-day mortality: 1.3% vs. 9.0% • ARI: 7.7%; NNH= 13 Hospital based • N=118 Cohort • Discontinued ASA therapy: Mortality and CV event HR 6.3 (1.3-31.3) Discontinuation of ASA in CV patients is associated with increased mortality. Sung et al. Ann Intern Med 2010. Derogar M et al. Clin Gastroenterol Hepatol 2013 Non-variceal upper GI bleeding: Platelet transfusion for life-threatening bleeding APAGE-APSDE: not recommended ASGE: an option for patients on antiplatelet agents BSG-ESGE: an option for patients on DOACs Non-variceal upper GI bleeding: Patient on DAPT APAGE-APSDE: continue aspirin, withhold second antiplatelet agent for up to 5 days after endoscopic haemostasis ASGE: discuss with cardiologist ESGE: continue aspirin, consult cardiologist for resumption of second antiplatelet agent CARDIOGASTROENTEROLOGY TIP Peri-Endoscopic Antiplatelet Management 1. Avoid stopping all antiplatelets simultaneously after PCI with stent insertion. 2. You must maintain patient on ASA monotherapy when stopping thienopyridine agents. 3. Avoid cessation of thienopyridine agents (even when ASA is continued) within the first 30 days of DES or BMS placement. 4. Avoid stopping DAPT in the first 90 days post-ACS. 5. Defer elective endoscopic procedures until patients finishes appropriate course of thienopyridine agents, possibly up to 12 months following DES placement. Anticoagulants: Site of Action • Circulation Research. 2014;114:1929-1943 Circulation Research. 2014;114:1929-1943 Oral Anticoagulants Bleeding complications in Warfarin users •Major haemorrhage in Warfarin users (intracranial, GI, GU and respiratory sites): 1–3% / person-year •The GI tract is the most common bleeding site (age-standardized incidence rate of 5.8 /1000 person-year). •Endoscopic findings are similar between VKA users and patients taking no anticoagulants with peptic ulcer being the main cause of bleeding . •VKAs-related GI bleeding events are associated with long hospitalization, relevant resource utilization, and a 30-day mortality of up to 15%. F. Radaelliet al. / Digestive and Liver Disease 47 (2015) 621–627 New oral anticoagulants (direct oral anticoagulants ,DOACs) •In general, DOACs reduce the risk of hemorrhagic stroke and have a comparable risk of major bleeding into all organs compared with warfarin. •DOACs are associated with a modestly increased risk of gastrointestinal (GI) bleeding compared with warfarin. •Warfarin increases the risk of major GI bleeding approximately 3-foldover placebo in the AF population, and 3 DOACs have been shown to further increase this risk 1.5- foldcompared with warfarin. Gastroenterology & Hepatology Volume 10, Issue 2 February 2014 The Rate of Major GIB in Non-valvular AF Population From The Three Pivotal trials Dabigatran 150 mg bid Rivaroxaban 20 mg OD Apixaban 5 mg BID HR for major GIB 1.49[CI 1.21-1.84] 1.61[CI 1.3-1.99] 0.89[CI 0.73-1.15] (VS. warfarin) Jay Desai; Jennifer M. Kolb; Jeffrey I. Weitz; James Aisenberg Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies . Thrombosis and Haemostasis 110.2/2013 Non-variceal upper GI bleeding: VKA 1. Assess the severity of bleeding ,Start hemodynamic resuscitation. 2. Discontinue the Anticoagulant if bleeding is more than minor. 3. Actively reverse the coagulation if bleeding is more than minor . 4. Assess for proper timing for endoscopy. 5. Determine the necessity and proper timing for re-instituationof Anticoagulant therapy. Pre-endoscopic management: VKA • Patients on VKAs • Timing of endoscopy* • After obtaining INR levels of 1.5–2.5 • Treatment options for VKA reversal • Vitamin K: II, VII, IX and X: IV infusion of 5–10 mg, infusion over a of 30 minutes • FFP: IV infusion of 15 mL/kg • PCCs: 3F-PCC, 4F-PCC, aPCC: 25–50 IU of factor IX/Kg • Recombinant factor VIIa (rFVIIa) *Gut1994;35:464–6. Annals of Internal Medicine 2010;152:101–13 Treatment options for VKA reversal VitK : •In bleeding patients, IV route is preferred over the oral one. •Vitamin K1 (phytomenadione), 10 mg (one ampoule) in 100 ml of 0.9% normal saline or 5% glucose solution: 10 ml over 10 minutes (1 mg/10 min) and the remaining over 30 minutes. •IV vitamin K is associated with an estimated 3/100 000 risk of anaphylaxis; thus,aslow infusion over a minimum of 30 minutes is advised to minimize this risk. •Following IV infusion of 5–10 mg vitamin K, the INR begins to decrease within 2–4 h and usually reaches a normal range within 24 h . Digestive and Liver Disease 47 (2015) 621–627 Treatment options for VKA reversal FFP: •The recommended dose : IV infusion of 15(10-30) mL/kg corresponding to about 3–4 units of plasma (one unit = 250 mL) in the average adult weighing 70 kg. •Half the dose can be repeated at 6 hours, as the half-life of the factors is 5 to 8 hours. •Cons : •large infusion volume, risk of fluid overload. •prolonged time needed to match blood group and to thaw and transport the units. •transfusion-related acute lung injury and a minimal risk of infection transmission •Time to effect of FFP is 10 min, but it takes a few hours for partial reversal of INR and at least 9 h for complete reversal (i.e.,INR< 1.5) F. Radaelliet al. / Digestive and Liver Disease 47 (2015) 621–627 Alberca-de-las-ParrasF. Clinical practice guidelines for managing coagulation in patients undergoing endoscopic procedures. Rev Esp Enferm Dig 2010; 102: 124-138.
Load more

Recommended publications
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Nutrition and Blood
    Greater Manchester Joint Formulary Chapter 9: Nutrition and Blood For cost information please go to the most recent cost comparison charts Contents 9.1. Anaemias and some other blood disorders 9.2 Fluids and electrolytes 9.3 Not listed 9.4. Oral nutrition 9.5 Minerals 9.6 Vitamins Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents Chapter 9 – page 1 of 16 V5.2 Greater Manchester Joint Formulary BNF chapter 9 Nutrition and Blood Section 9.1. Anaemias and some other blood disorders Subsection 9.1.1 Iron-deficiency anaemias Subsection 9.1.1.1 Oral iron First choice Ferrous fumarate 322 mg tabs (100 mg iron) Ferrous fumarate 305 mg caps (100 mg iron) Alternatives Ferrous fumarate 210 mg tabs (68 mg iron) Ferrous sulphate 200 mg tabs (65 mg iron) Ferrous fumarate 140 mg sugar free syrup (45 mg of iron/5 mL) Sodium feredetate 190 mg sugar free elixir (27.5 mg of iron/5 mL) Grey drugs Ferric maltol capsules Items which Criterion 2 (see RAG list) are listed as For treatment of iron deficiency anaemia in patients with Grey are intolerance to, or treatment failure with, two oral iron deemed not supplements.
    [Show full text]
  • Vitamin K1 (Phytomenadione) 2021 Newborn Use Only
    Vitamin K1 (Phytomenadione) 2021 Newborn use only Alert Check ampoule carefully as an adult 10 mg ampoule (Konakion MM Adult) is also available. USE ONLY Konakion MM Paediatric. Vitamin K Deficiency Bleeding is also known as Haemorrhagic Disease of Newborn (HDN) Indication Prophylaxis and treatment of vitamin K deficiency bleeding (VKDB) Action Fat soluble vitamin. Promotes the activation of blood coagulation Factors II, VII, IX and X in the liver. Drug type Vitamin. Trade name Konakion MM Paediatric. Presentation 2 mg/0.2 mL ampoule. Dose IM prophylaxis (Recommended route)(1) Birthweight ≥ 1500 g - 1 mg (0.1 mL of Konakion® MM) as a single dose at birth. Birthweight <1500 g - 0.5 mg (0.05 mL of Konakion® MM) as a single dose at birth. Oral prophylaxis(1) 2 mg (0.2 mL of Konakion® MM) for 3 doses: First dose: At birth. Second dose: 3–5 days of age (at time of newborn screening) Third dose: During 4th week (day 22-28 of life). It is imperative that the third dose is given no later than 4 weeks after birth as the effect of earlier doses decreases after this time. Repeat the oral dose if infant vomits within an hour of an oral dose or if diarrhoea occurs within 24 hours of administration. IV Prophylaxis (5) May be given in sick infants if unable to give IM or oral injection. 0.3 mg/kg (0.2-0.4 mg/kg) as a single dose as a slow bolus (maximum 1 mg/minute). Dose can be repeated weekly. IV treatment of Vitamin K deficiency bleeding (VKDB) 1 mg IV as a slow bolus (maximum 1 mg/minute).
    [Show full text]
  • VITAMIN K SUBSTANCES 1. Exposure Data
    VITAMIN K SUBSTANCES Vitamin K comprises a group of substances, which are widespread in nature and are an essential co-factor in humans in the synthesis of several proteins that play a role in haemostasis and others that may be important in calcium homeostasis. The K vitamins all contain the 2-methyl-1,4-naphthoquinone (menadione) moiety, and the various naturally occurring forms differ in the alkyl substituent at the 3-position. Phylloquinone (vitamin K1) is 2-methyl-3-phytyl-1,4-naphthoquinone and is widely found in higher plants, including green leafy vegetables, and in green and blue algae. The menaquinones (formerly vitamin K2) have polyisoprenyl substituents at the 3-position and are produced by bacteria. The compound menadione (formerly vitamin K3) lacks an alkyl group at the 3-position but can be alkylated in vivo in some species. Several synthetic water-soluble derivatives, such as the sodium diphosphate ester of menadiol and the addition product of menadione with sodium bisulfite, also have commercial applications (National Research Council, 1989; Gennaro, 1995; Weber & Rüttimann, 1996). 1. Exposure Data 1.1 Chemical and physical data 1.1.1 Nomenclature, structural and molecular formulae and relative molecular masses Vitamin K (generic) Chem. Abstr. Serv. Reg. No.: 12001-79-5 Chem. Abstr. Name: Vitamin K Vitamin K1 (generic) Chem. Abstr. Serv. Reg. No.: 11104-38-4 Chem. Abstr. Name: Vitamin K1 Phylloquinone Chem. Abstr. Serv. Reg. No.: 84-80-0 Deleted CAS Reg. Nos.: 10485-69-5; 15973-57-6; 50926-17-5 –417– 418 IARC MONOGRAPHS
    [Show full text]
  • Vitamin K1 (Phytomenadione) 2021 Newborn Use Only
    Vitamin K1 (Phytomenadione) 2021 Newborn use only Alert Check ampoule carefully as an adult 10 mg ampoule (Konakion MM Adult) is also available. USE ONLY Konakion MM Paediatric. Vitamin K Deficiency Bleeding is also known as Haemorrhagic Disease of Newborn (HDN) Indication Prophylaxis and treatment of vitamin K deficiency bleeding (VKDB) Action Fat soluble vitamin. Promotes the activation of blood coagulation Factors II, VII, IX and X in the liver. Drug type Vitamin. Trade name Konakion MM Paediatric. Presentation 2 mg/0.2 mL ampoule. Dose IM prophylaxis (Recommended route)(1) Birthweight ≥ 1500 g - 1 mg (0.1 mL of Konakion® MM) as a single dose at birth. Birthweight <1500 g - 0.5 mg (0.05 mL of Konakion® MM) as a single dose at birth. Oral prophylaxis(1) 2 mg (0.2 mL of Konakion® MM) for 3 doses: • First dose: At birth. • Second dose: 3–5 days of age (at time of newborn screening) • Third dose: During 4th week (day 22-28 of life). • It is imperative that the third dose is given no later than 4 weeks after birth as the effect of earlier doses decreases after this time. • Repeat the oral dose if infant vomits within an hour of an oral dose or if diarrhoea occurs within 24 hours of administration. IV Prophylaxis (5) May be given in sick infants if unable to give IM or oral injection. 0.3 mg/kg (0.2-0.4 mg/kg) as a single dose as a slow bolus (maximum 1 mg/minute). Dose can be repeated weekly. IV treatment of Vitamin K deficiency bleeding (VKDB) 1 mg IV as a slow bolus (maximum 1 mg/minute).
    [Show full text]
  • 191.3 Protocol for Over-Anticoagulation with Warfarin
    191.3 PROTOCOL FOR OVER-ANTICOAGULATION WITH WARFARIN High INR, patient not bleeding ¾ If INR ≥5, omit warfarin for 1 - 2 days. ¾ If INR ≥8, give 1 to 5 mg vitamin k (phytomenadione – Konakion MM Paediatric® - unlicensed) by mouth. ¾ Occasional patients with INR ≥8 and a very high risk of thrombosis may be more safely managed without vitamin K - seek senior advice. Restart warfarin, if still required, once INR <5. Consider cause of raised INR and adjust maintenance dose. Non-major bleeding 1 to 3 mg vitamin k (phytomenadione) by IV bolus (1 to 5 mg vitamin k by mouth may be more appropriate in the community or in some inpatients). ¾ Consider cause of bleeding (especially if INR in therapeutic range). ¾ See note above regarding patients at very high thrombotic risk. For oral cavity bleeding consider tranexamic acid 250 mg/5 ml mouthwash (unlicensed) – 5 to 10 ml 8 hourly. Major/life-threatening haemorrhage (e.g. CNS/major GI) ¾ Discuss with consultant haematologist. ¾ 5 mg vitamin k (phytomenadione) IV immediately (prior to INR result). ¾ Prothrombin complex concentrate (Octaplex) Dose: 25 units/kg rounded to nearest 500 unit vial i.e. 3 bottles (1500 units) for patients approximately 60 kg 4 bottles (2000 units) for patients approximately 70 kg 5 bottles (2500 units) for patients of 80 kg or more FFP is a less effective alternative. ¾ See Appendix 1 for advice and reconstitution of Octaplex. Note the product SPC advises a maximum administration rate of 3 ml/min. However long-standing clinical practice and published evidence2 shows that a rate of up to 10 ml/min is safe.
    [Show full text]
  • Dekas in Cystic Fibrosis Multivitamin and Mineral Dietary Supplement For
    DEKAs in Cystic Fibrosis All-in-one Multivitamin & Mineral Dietary Supplement with Enhanced Absorption Roberto Jongejan, MD, PhD Gus Papas, MD, MPH Vitamin Malabsorption in Cystic Fibrosis In cystic fibrosis, pancreatic insufficiency and a diminished bile acid pool lead to malabsorption and deficiencies of fat-soluble vitamins such as vitamins D, E, K and A. These vitamin deficiencies can lead to significant morbidity in cystic fibrosis patients, especially as they are living longer. 2 DEKAs/AquADEKs Micellar Delivery Technology Clinically studied1,2 DEKAs delivery technology has been clinically proven to increase the absorption of fat-soluble vitamins and other lipophilic compounds in conditions of malabsorption such as in cholestastic liver disease and cystic fibrosis.1,2 1. Papas K, Kalbfleisch J, Mohon R, DOI 10.1007/s10620-006-9489-2 2. Argao E, Heubi JE, Hollis BW, et al., DOI: 10.1203/00006450-199202000-00011 3 DEKAs Product Concept Registered as Food for Special Medical Purposes* Use under medical supervision DEKAs provides in one serving: 1. Complete coverage of doses of fat-soluble vitamins as recommended in CF guidelines 2. Standard doses of water soluble vitamins, minerals and anti-oxidants DEKAs Plus provides all the vitamins A,B,C,D,E,K, zinc, selenium and anti-oxidants in: 1. DEKAS Plus liquid – for infants and children up to 4 years of age 2. DEKAs Plus softgels and chewable tablets – for children 4 years of age and older and adults DEKAs Essential is for dose titration or stand alone use 1. DEKAs Essential can be used if adequate serum levels of fat soluble vitamins are not obtained with DEKAs Plus softgels or chewable tablets.
    [Show full text]
  • Guideline 191FM Protocol for Over-Anticoagulation with Warfarin
    191FM.7 PROTOCOL FOR OVER-ANTICOAGULATION WITH WARFARIN High International Normalised Ratio (INR), patient not bleeding • If INR ≥5 and <8, omit warfarin for 1 - 2 days. • If INR ≥8, stop warfarin until INR <5, give 1 to 5 mg phytomenadione orally (vitamin k). Use Konakion MM Paediatric®. Note this is unlicensed. • Occasional patients with INR ≥8 and a very high risk of thrombosis may be more safely managed without phytomenadione - seek senior advice. Restart warfarin, if still required, once INR <5, consider cause of raised INR and adjust maintenance dose. • Oral phytomenadione will have an effect within 16 - 24 hours. Non-major bleeding INR 5.0 or greater • Omit warfarin. • Give 1 to 3 mg phytomenadione by IV bolus. Note: 1 to 5 mg phytomenadione by mouth may be more appropriate in the community or in some inpatients (e.g. if no IV access, depending on how significant the bleed is). If anticoagulation is to be stopped, consider 5 – 10 mg phytomenadione orally or IV (larger dose to be used if there is a plan for no further anticoagulation). • Restart warfarin, if still required, once INR <5. INR less than 5 • A clinical decision needs to be made as to whether lowering the INR is required. If this is the case, consider giving IV phytomenadione 1 - 3 mg and modifying warfarin dose. Omit warfarin • General haemostatic measures • For oral cavity bleeding consider tranexamic acid 250 mg/5 ml mouthwash (unlicensed) – 5 to 10 ml 8 hourly. • Consider cause of bleeding (especially if INR in therapeutic range). • Repeat INR following day • See note above regarding patients at very high thrombotic risk.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Prothrombin Complex Concentrate (PCC) Guidelines
    Prothrombin Complex Concentrate Guidelines V3.0 Document Control Title Prothrombin Complex Concentrate (PCC) Guidelines Author Author’s job title Clinical Nurse Specialist, Intravascular Fluid Management Directorate Department Planned Care Transfusion Date Version Status Comment / Changes / Approval Issued 1.0 May Final Approved by the Drugs, Therapeutics and Transfusion 2007 Group. The Beriplex Guidelines were revised into the new format. 1.1 Mar Revision Octaplex replaced Beriplex as the only licensed PCC at 2008 the time, this dosing has now been reviewed to provide clarity 1.2 Aug Revision Amends to ensure corporate identify requirements 2008 1.3 Feb Revision Minor amendment regarding hospital contact. 2009 1.4 Dec Revision Minor amendments by Corporate Affairs, prior to re- 2010 approval: dropped into latest template for document map navigation, hyperlink to procedural document. 2.0 Dec Final Additions to abbreviations, contact numbers and contra- 2010 indications. Clarification on prescribing documentation. Approved by Hospital Transfusion Committee on 14th December 2010. 2.1 March Revision Addition to section 5.4 agreed at Hospital Transfusion 2011 Team meeting 1st March 2011. Minor amendments to document control report and footer by Corporate Affairs. 2.2 Dec Revision Amendment to section 5.1 agreed at Hospital Transfusion 2011 Team meeting 29th November 2011. 2.3 May Revision Minor amendments by Corporate Governance Manager to 2012 headers and footers, document control report, formatting for document map navigation and table of contents. Applicable staff refined. 2.4 Jan Revision Reviewed by HTT 21st Jan 2014. References updated. 2014 Requesting Octaplex® clarified. 2.5 Feb Revision Updated to new Trust Template.
    [Show full text]
  • A Life-Sustaining Single Dose of Recombinant Activated Factor VII for an Egyptian Patient with Hemorrhagic Crisis
    The role of FNAC in the diagnosis of peripheral lymphadenopathy electron microscopy, and flow cytometry.1 Also, the surgical biopsy. However, due to its limitations, it does number of unsatisfactory smears of 8.8% is within not totally replace surgical biopsy in the investigation of the reported range in the literature.2 The problem of peripheral lymphadenopathy. false positivity, a worrisome aspect of FNAC is not reported in this study, as none of the smears with Received 21st August 2006. Accepted 20th January 2007. reactive hyperplasia were interpreted as tuberculous, From the Department of Surgery (Al-Abkari), Dammam Central Hospital, and lymphoma, or metastatic carcinoma. Our results in this the Regional Laboratory and Blood Bank (Butt, Al-Abkari, Ahmed), Dammam, series reported high rates of false negative in tuberculous Eastern Province, Kingdom of Saudi Arabia. Address correspondence and lymphadenitis (55%), which is significantly higher reprint requests to: Dr. Hussein A. Al-Abkari, PO Box 60535, Qatif 31911, than reported in the literature.5 These were interpreted Kingdom of Saudi Arabia. Tel. +966 5005800870. Fax. +966 (3) 8155618. as reactive hyperplasia. This may be explained by the E-mail: [email protected] fact that tuberculous lymphadenitis frequently displays changes that are compatible with nonspecific reactive References hyperplasia. Sometimes only a few epithelioid cells are 1. Nasuti JF, Yu G, Boudousquie A, Gupta P. Diagnostic value found in small groups or as single cells, or the histiocytes of lymph node fine needle aspiration cytology: an institutional may have the typical appearance of epithelioid cells. The experience of 387 cases observed over a 5-year period.
    [Show full text]
  • Vitalipid® N Adult and Infant
    AUSTRALIAN PRODUCT INFORMATION - VITALIPID® N ADULT and VITALIPID® N INFANT (RETINOL PALMITATE, ERGOCALCIFEROL, DL-ALPHA-TOCOPHEROL, PHYTOMENADIONE) 1 NAME OF MEDICINE Retinol palmitate (Vitamin A) Ergocalciferol (Vitamin D2) dl-alpha-tocopherol (Vitamin E) Phytomenadione (Vitamin K1) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL contains: Adult Infant Active Ingredients Retinol palmitate (Vitamin A) 99 g 69 g Ergocalciferol (Vitamin D2) 0.5 g 1.0 g dl-alpha-tocopherol (Vitamin E) 0.91 mg 0.64 mg Phytomenadione (Vitamin K1) 15 g 20 g 10 mL ampoule contains: Adult Infant Retinol palmitate (Vitamin A) 990 g (3300 IU) 690 g (2300 IU) Ergocalciferol (Vitamin D2) 5 g (200 IU) 10 g (400 IU) dl-alpha-tocopherol (Vitamin E) 9.1 mg 10 IU) 6.4 mg (7.0 IU) Phytomenadione (Vitamin K1) 150 g 200 g Excipients with known effect: Soya oil, Egg lecithin For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Concentrated Emulsion for Injection. A milky white emulsion. Sterile oil/water emulsion with pH: approx..8 and osmolality: approx. 300 mOsm/kg water. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Vitalipid N Adult is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1. Vitalipid N Infant is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1 in paediatric patients up to 11 years of age. 4.2 Dose and method of administration Must be diluted before use: Adults and children aged 11 years and above.
    [Show full text]